PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 9.54

Change

-0.27 (-2.75)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

-1.98 (-6.25%)

USD 11.50B
QLD ProShares Ultra QQQ

-0.31 (-0.28%)

USD 7.95B
FNGU MicroSectors FANG+ Index 3X Le..

+1.65 (+0.31%)

USD 5.90B
SSO ProShares Ultra S&P500

+0.10 (+0.10%)

USD 5.68B
UPRO ProShares UltraPro S&P500

+0.12 (+0.13%)

USD 4.34B
TECL Direxion Daily Technology Bull..

-0.57 (-0.59%)

USD 3.15B
YINN Direxion Daily FTSE China Bull..

-0.20 (-0.71%)

USD 2.02B
USD ProShares Ultra Semiconductors

-2.21 (-3.08%)

USD 1.40B
LABU Direxion Daily S&P Biotech Bul..

-2.08 (-1.58%)

USD 0.99B
DPST Direxion Daily Regional Banks ..

-2.87 (-1.91%)

USD 0.88B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.10% 52% F 77% C+
Dividend Return 1.01% 52% F 17% F
Total Return 24.10% 52% F 76% C+
Trailing 12 Months  
Capital Gain 77.65% 70% C- 94% A
Dividend Return 2.16% 63% D 30% F
Total Return 79.81% 70% C- 94% A
Trailing 5 Years  
Capital Gain -39.03% 29% F 12% F
Dividend Return 1.79% 31% F 5% F
Total Return -37.24% 27% F 10% F
Average Annual (5 Year Horizon)  
Capital Gain 50.74% 78% C+ 94% A
Dividend Return 51.24% 78% C+ 93% A
Total Return 0.49% 38% F 12% F
Risk Return Profile  
Volatility (Standard Deviation) 368.36% 15% F 3% F
Risk Adjusted Return 13.91% 28% F 32% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.